Overview

• Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and Alphabet.
• The funding will accelerate the development of its next-generation AI drug design engine and support its mission to transform drug discovery and address major diseases.
• The company plans to expand its workforce and advance its internal programs, including oncology and immunology, toward clinical development by the end of 2025.
• Isomorphic Labs leverages DeepMind’s AlphaFold technology, which predicts protein structures, as a cornerstone of its AI-driven drug discovery efforts.
• Strategic partnerships with pharmaceutical giants Eli Lilly and Novartis remain central to its efforts, with multi-billion-dollar milestone agreements in place.